Antibody-functionalized theranostic protein nanoparticles for the synergistic deep red fluorescence imaging and multimodal therapy of ovarian cancer

Borlan, Raluca; Focșan, Monica; Perde-Schrepler, Maria; Şoriţău, Olga; Campu, Andreea; Gaina, Luiza; Páll, Emöke; Pop, Bogdan; Baldasici, Oana; Gherman, Claudia; Stoia, Daria; Maniu, Dana; Aştilean, Simion

doi:10.1039/d1bm01002f

Cited by 4 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the 0.23 ns increase in the lifetime decay time of antibody‐decorated NPs compared to undecorated NPs suggests the existence of different intracellular localization and/or internalization pathways of the fluorescent agent when FRα is involved. Although further in vivo investigations are needed, HSA&phthaloNO 2 ‐AB NPs have great optical potential as FRα‐targeted FLI nanosized agents 59 …”

Section: Membrane‐associated Targetsmentioning

confidence: 99%

Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery

Solidoro,

Centonze,

Miciaccia

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological cancer, with a survival rate of approximately 40% at five years from the diagno. The first‐line treatment consists of cytoreductive surgery combined with chemotherapy (platinum‐ and taxane‐based drugs). To date, the main prognostic factor is related to the complete surgical resection of tumor lesions, including occult micrometastases. The presence of minimal residual diseases not detected by visual inspection and palpation during surgery significantly increases the risk of disease relapse. Intraoperative fluorescence imaging systems have the potential to improve surgical outcomes. Fluorescent tracers administered to the patient may support surgeons for better real‐time visualization of tumor lesions during cytoreductive procedures. In the last decade, consistent with the discovery of an increasing number of ovarian cancer‐specific targets, a wide range of fluorescent agents were identified to be employed for intraoperatively detecting ovarian cancer. Here, we present a collection of fluorescent probes designed and developed for fluorescence‐guided ovarian cancer surgery. Original articles published between 2011 and November 2022 focusing on fluorescent probes, currently under preclinical and clinical investigation, were searched in PubMed. The keywords used were targeted detection, ovarian cancer, fluorescent probe, near‐infrared fluorescence, fluorescence‐guided surgery, and intraoperative imaging. All identified papers were English‐language full‐text papers, and probes were classified based on the location of the biological target: intracellular, membrane, and extracellular.

show abstract

Section: Membrane‐associated Targetsmentioning

confidence: 99%

Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery

Solidoro,

Centonze,

Miciaccia

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…[121] Nevertheless, the noteworthy advantages of the EDC/NHS chemistry make it a traditional method for the convenient and stable conjugation between antibodies and nanoparticles. [107,[122][123][124][125][126][127][128][129][130][131][132]…”

Section: -Ethyl-3-(3-dimethylaminopropyl)carbodiimide/n-hydroxysuccin...mentioning

confidence: 99%

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Chen

2022

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Cancer remains as one of the most significant diseases that seriously threatens human health all over the world. − In order to effectively inhibit malignant tumor and prolong survival, varieties of drug delivery systems and polymer prodrugs have been developed. − However, most of them are restricted by their low drug loading capacity, and serious cumulative cytotoxicity. , By comparison, small-molecule prodrugs − have the advantage of high loading capacity and easy metabolism for cancer therapeutics. Typically, Yan et al developed an amphiphilic small-molecule prodrug by integrating a hydrophilic anticancer drug and a hydrophobic anticancer drug via a hydrolyzable ester linkage and proposed the concept of amphiphilic drug–drug conjugate (ADDC), which opens up a new way for self-delivery systems.…”

Section: Introductionmentioning

confidence: 99%

Self-Assembled Lenalidomide/AIE Prodrug Nanobomb for Tumor Imaging and Cancer Therapy

Mai,

Cao,

Cheng

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

To develop multifunctional small-molecule prodrugs is highly desirable for cancer treatment but remains challenging in intrinsic traceability. As an acid-cleavable linkage, a Schiff bases benefiting from its distinctive fluorescence quenching ability was selected to prepare a small-molecule prodrug with cancer-targeted and self-indicating. In this study, we designed and developed a multifunctional self-assembled nanobomb of amphiphilic TPE-Lenalidomide prodrug, which comprises a hydrophobic aggregation-induced emission (AIE) probe 4-(1,2,2triphenylvinyl)benzaldehyde (TPE-CHO) and a hydrophilic anticancer drug Lenalidomide via a Schiff base linkage. We investigated the synergistic effect of d-PET and C�N isomerization which would keep the fluorescence of TPE-Lenalidomide in the "always off" state by density functional theory (DFT) calculation. Once reaching the pathological site, such a vesicular nanobomb of TPE-Lenalidomide will be acidolyzed to release the AIE probe and Lenalidomide molecules simultaneously, consequently realizing high-efficiency effects of tumor imaging and cancer therapy (cell viability: normal cell L929, ∼79.49%; cancer cell 4T1, ∼27.08%; p = 0.000118). This work may pave an avenue to prepare small-molecule prodrugs for tumor-targeted diagnosis and cancer therapy.

show abstract

Antibody-functionalized theranostic protein nanoparticles for the synergistic deep red fluorescence imaging and multimodal therapy of ovarian cancer

Abstract: Among women, ovarian cancer is the fifth most frequent type of cancer, and despite benefiting from the current standard treatment plan, 90% of patients relapse in the next 18 months...

Cited by 4 publications

References 50 publications

Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery

Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Self-Assembled Lenalidomide/AIE Prodrug Nanobomb for Tumor Imaging and Cancer Therapy

Contact Info

Product

Resources

About